Hong Kong SAR

Enerchina Holdings’s HK$1.3bn ($165.7m) rights issue in Hong Kong failed to get enough support from investors.

Investors queued up on Thursday to buy Beijing Enterprises Water Group's (BEWG) second Panda bond in two months. The deal came as property Panda issuers are held up by regulators in the pipeline, as China seeks to cool its housing market.

China’s Texhong Textile Group has returned to the offshore loan market for a HK$1bn ($127m) fundraising.

Qilu Expressway’s underwriters have stepped in after the company's HK$1.3bn ($159.3m) Hong Kong IPO fell short in both the institutional and retail tranches.

To do, or not to do? That appears to be the question plaguing China’s stock exchanges when it comes to including weighted voting rights shares on the Stock Connect’s southbound trading channel. A rather vague consensus has been reached with the Hong Kong bourse, but what does this mean for the city’s equities markets? Jonathan Breen finds out.

Hong Kong’s Securities and Futures Commission has sanctioned a former Standard Chartered executive in Hong Kong for IPO-related offences.

Citi has made a handful of senior level changes to its loans and acquisition finance team in Asia Pacific, according to three internal memos seen by GlobalCapital Asia.

Shanghai Fosun Pharmaceutical Group bagged HK$2.6bn ($331m) from an H-share placement on Wednesday, its first capital raise in more than a year.

Debt syndicate head exits ANZ – Malhotra named India IB, ECM chief at HSBC – ICBC International appoints syndications head – HSBCBS fined for bond sale breaches

Ascletis Pharma is in the market with the first biotechnology IPO in Hong Kong following the bourse’s historic change in listing rules.

JP Morgan pocketed $350m on Tuesday from a cash-settled exchangeable bond that was the first of its kind in Asia, drawing huge support from long-only investors. The deal is among a handful globally that not only lets bank issuers raise funds, but also helps with hedging out their corporate derivative exposure. John Loh reports.

Chinese firm Ascletis Pharma has launched bookbuilding for a HK$3.58bn ($456.9m) IPO, the first company to take advantage of the Hong Kong Stock Exchange’s new biotechnology-friendly listing regime.